Exploration of Metabolic Alterations in Methylmalonic Acidemia across Distinct Genetic Backgrounds Authors: Hai-Juan Zhi, Yi Ding, Yu-Xin Deng, Ting Chen, Yue Cao, Si-Yu Chang, Xia Zhan, Feng Xu, Li-Li Hao, Li-Li Liang, Wen-Juan Qiu, Hui-Wen Zhang, Xue-Fan Gu, Lian-Shu Han Published: 2026 ABSTRACT Methylmalonic acidemia (MMA) is a rare recessively inherited disorder mainly caused by variants in the MMUT and MMACHC genes, leading to the accumulation of methylmalonic acid. The pathophysiological mechanisms of MMA remain poorly understood, and treatments are symptomatic. This study investigated the comprehensive metabolic remodeling signatures of the MMA subtypes. We applied targeted metabolomics to dried blood spot (DBS) samples obtained from a Chinese cohort of 85 patients, consisting of 42 MUT-MMA, 23 CblC-MMA, and an additional 20 CblC-MMA presenting kidney injury and pulmonary arterial hypertension (PAH) as the initial symptoms. In addition, metabolite alterations were also assessed following treatments adopting a reduction analysis. The targeted metabolomics study highlighted the presence of significant differences among the MMA subtypes. New biomarkers (carbohydrates and short-chain fatty acids) were proposed for MUT, while novel data regarding the alterations of unsaturated fatty acid profiles and biomarkers of phenylalanine, tyrosine, and tryptophan biosynthesis were obtained for CblC disease. We also revealed the metabolic remodeling signatures in MMA patients following treatment. Additionally, key differences were identified between the CblC-MMA-presenting kidney injury and PAH populations, particularly regarding phenylacetylglutamine and isovalerylcarnitine, which may serve as discriminatory biomarkers for these subtypes. These findings provide a robust metabolic framework that facilitates precise subtype diagnosis, therapeutic monitoring, and a mechanistic understanding of MMA heterogeneity. Introduction Methylmalonic acidemia (MMA), inherited in an autosomal recessive mode, is characterized by methylmalonic acid accumulation in body fluids, and it has an overall incidence estimated at 1:15,000 in China. , MMA patients exhibit neurological and gastrointestinal disorders with common symptoms such as lethargy, seizures, and anorexia. The outcome of MMA varies from mild to life-threatening, and the treatment is complex, requiring regular monitoring and frequent therapeutic and dietary adjustments. ,, MMA is mainly caused by deficiency in the activity of methylmalonyl-CoA mutase (MUT-MMA) or in the metabolism of cobalamin C (CblC-MMA). , Clinically, MUT-MMA present with recurrent attacks of metabolic decompensation, mainly characterized by acidosis, hyperammonemia, ketosis, and elevated blood lactate. , Patients with CblC present the major involvement of the central nervous system with neurocognitive impairment and develop a multisystem disease with kidney injury, pulmonary arterial hypertension (PAH), and progressive visual dysfunction. − Biochemically, MUT and CblC accumulate “primary” metabolites including methylmalonic acid, 3-hydroxypropionic acid, 2-methylcitric acid, and propionylcarnitine, all derived from un-metabolized propionyl-CoA. ,, Methionine synthase defect in CblC causes homocysteine accumulation and methionine reduction. The levels of 2-methylcitric acid, propionylcarnitine, and methylmalonic acid have demonstrated closely clinical relevance in MUT. Elevated homocysteine in CblC causes diffuse macroangiopathic damage. These abnormalities stand for the biochemical hallmarks that could specially characterize MUT and CblC subtypes. These primary metabolites are utility for diagnosis and the treatment response in MMA patients. − However, it is also necessary to explore new metabolites that could enhance understanding of the pathophysiology and allow for developing new treatment strategies. Furthermore, considering the clinical manifestation overlaps among different MMA subtypes, metabolomics allows for the overall evaluation of metabolic pathways associated with specific MMA, thus enabling fast and specific identification of the affected metabolism. − CblC-MMA accounts for 75–80% of the MMA cases in China. , The kidney and lung complications of this disease have been described in a small number of cases. ,,, Our previous research also pointed out that among the CblC defects enrolled, 17 patients had kidney symptoms as their initial presentation and 7 presented PAH. Investigation on patients with the rare combination of PAH and renal thrombotic microangiopathy also revealed that CblC deficiency was the underlying cause in these children. Another retrospective analysis of pediatric patients diagnosed with PAH pointed out that these patients carried compound heterozygous mutations in the MMACHC gene and improved significantly after being treated for CblC deficiency. Furthermore, whole exome sequencing performed on patients with diffuse lung disease confirmed a compound heterozygosity in the MMACHC gene. However, despite an increasing number of CblC patients having kidney injury (CblC_K) and PAH (CblC_P) as initial symptoms, the related pathophysiology remains poorly understood. Metabolomic studies of CblC-associated kidney injury and PAH have not been comprehensively conducted before. Increased metabolic insight into the exact pathophysiological events underlying CblC could potentially pave the way toward optimized clinical care and better outcomes. In this work, we studied the metabolomic profiles of the main MMA subtypes to determine comprehensive disease-specific biomarker signatures, aiming to provide novel insights into the biological and pathophysiological differences between the MMA subtypes, which are crucial for rare conditions. Methods Study Population In the current study, dried blood spot (DBS) samples from a total of 132 participants were included, consisting of 85 patients with MMA and 47 healthy controls (Tables and ). Among the MMA patients, there were 42 in MUT, 23 in CblC, 12 in CblC_K, and 8 in CblC_P. 1Study Population’s Basic Information and Clinical Characteristics, characteristicscontrolMUTCblCCblC-KCblC-Ptotal (n)474223128age (month), median (range)2.80 (0.37–168)2.30 (0.40–216.00)1.37 (0.37–228.00)66.00 (3.00–240.00)8.50 (1.97–204.00)gender (n) female25131054male22291374biochemical features C3 (μmol/L), median (IQR)1.11 (0.77–1.35)15.17 (10.10–26.16)7.13 (4.85–8.73)5.44 (3.92–11.36)7.26 (4.29–9.41)C3/C2 ratio, median (IQR)0.07 (0.06–0.09)0.74 (0.57–0.98)0.78 (0.59–0.96)0.24 (0.19–0.29)0.29 (0.24–0.34)aAbbreviations: C3, propionylcarnitine; C2, acetylcarnitine; CblC, cobalamin C type methylmalonic acidemia; CblC_K, cobalamin C type methylmalonic acidemia with kidney injury; CblC_P, cobalamin C type methylmalonic acidemia with pulmonary arterial hypertension; and MUT, methylmalonyl-CoA mutase type methylmalonic acidemia.bNormal reference range of blood C3: 0.5–4.0 μmol/L; normal reference range of blood C3/C2 ratio: 0.04–0.2. Study Population’s Basic Information and Clinical Characteristics, Abbreviations: C3, propionylcarnitine; C2, acetylcarnitine; CblC, cobalamin C type methylmalonic acidemia; CblC_K, cobalamin C type methylmalonic acidemia with kidney injury; CblC_P, cobalamin C type methylmalonic acidemia with pulmonary arterial hypertension; and MUT, methylmalonyl-CoA mutase type methylmalonic acidemia. Normal reference range of blood C3: 0.5–4.0 μmol/L; normal reference range of blood C3/C2 ratio: 0.04–0.2. 2Pairwise Study Population’s Basic Information and Clinical Characteristics, characteristicsMUT-pairwiseCblC-pairwiseCblC_K-pairwisetotal (n)30145age (month), median (range)2.30 (0.40–216.00)0.93 (0.37–120.00)168.00 (132.00–240.00)gender (n) female862male2283biochemical featuresMUT-beforeMUT-afterCblC-beforeCblC-afterCblC_K-beforeCblC-K-afterC3 (μmol/L), median (IQR)15.00 (8.66–27.60)17.42 (6.48–23.53)6.89 (4.92–8.50)1.92 (1.50–2.57)4.47 (2.25–5.50)3.05 (2.47–3.13)C3/C2 ratio, median (IQR)0.68 (0.55–0.97)0.49 (0.32–0.63)0.79 (0.63–0.95)0.13 (0.08–0.17)0.19 (0.16–0.30)0.13 (0.10–0.13)aAbbreviations: C3, propionylcarnitine; C2, acetylcarnitine; CblC, cobalamin C type methylmalonic acidemia; CblC_K, cobalamin C type methylmalonic acidemia with kidney injury; and MUT, methylmalonyl-CoA mutase type methylmalonic acidemia.bNormal reference range of blood C3: 0.5–4.0 μmol/L; normal reference range of blood C3/C2 ratio: 0.04–0.2. Pairwise Study Population’s Basic Information and Clinical Characteristics, Abbreviations: C3, propionylcarnitine; C2, acetylcarnitine; CblC, cobalamin C type methylmalonic acidemia; CblC_K, cobalamin C type methylmalonic acidemia with kidney injury; and MUT, methylmalonyl-CoA mutase type methylmalonic acidemia. Normal reference range of blood C3: 0.5–4.0 μmol/L; normal reference range of blood C3/C2 ratio: 0.04–0.2. Diagnosis of MMA was based on clinical manifestations, abnormal levels of diagnostic metabolites (propionylcarnitine, propionylcarnitine/acetylcarnitine ratio), and genetic results of at least one pathogenic variant in MMUT or MMACHC gene. PAH diagnosis was based on pulmonary artery systolic pressure (PASP), which was above 40 mmHg. Kidney injury was defined as an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2 or the presence of albuminuria. Because of the rare occurrence of MMA, strict age matching in the complicated CblC groups would not be reasonable. Furthermore, patients with CblC deficiency complicated by lung injury and pulmonary hypertension generally present with the late onset phenotype; consequently, the two groups are significantly older than the other cohorts. Among the MUT patients, none had kidney impairment or had undergone kidney transplantation. Treatment varies with the difference in vitamin B12 responsiveness and is adjusted depending on the individual conditions. The standard treatment for MMA patients included a protein-restricted diet, l-carnitine supplementation (50–100 mg/kg/day), betaine (50–100 mg/kg/day), folic acid (5–10 mg/day), and intramuscular injections of hydroxocobalamin (1–10 mg/day). , Samples from the normal population were tested on a biochemical platform, and the measured levels of amino acids, acylcarnitines, and organic acids were all within the normal reference ranges. These results were reviewed by physicians from the Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, confirming that the subjects did not fall into the categories of rare inherited metabolic disorders or other metabolic disorders. This study was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine (approval number: XHEC-D-2025-090). Quantitative Mass Spectrometry-Based Metabolomics DBS metabolomic profiling was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based targeted metabolomics analysis (Q300 kit, Metabo-Profile, Shanghai, China). Briefly, three 3.2 mm disks from each DBS were transferred into a 96-well plate and 20 μL of ultrapure water was added to each well. After extraction and derivatization, the supernatant was transferred to a new 96-well plate with 10 μL internal standards added to each well and used for subsequent LC-MS/MS analysis. More details are presented in Supporting Methods. Quantitative analysis of functional small molecule metabolites was performed using an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA). Chromatographic separation was achieved on an ACQUITY UPLC BEH C18 analytical column (2.1 × 100 mm2, 1.7 μm) equipped with a VanGuard pre-column (2.1 × 5 mm2, 1.7 μm), maintained at a column temperature of 40 °C and a sample manager temperature of 10 °C. The mobile phase consisted of water containing 0.1% formic acid (A) and acetonitrile/isopropanol (70:30, v/v) (B) at a flow rate of 0.40 mL/min with an injection volume of 5.0 μL. The gradient elution program was as follows: 0–1 min, 5% B; 1–5 min, 5–30% B; 5–9 min, 30–50% B; 9–11 min, 50–78% B; 11–13.5 min, 78–95% B; 13.5–14 min, 95–100% B; 14–16 min, 100% B; 16–16.1 min, 100–5% B; and 16.1–18 min, 5% B. The mass spectrometer was operated with a capillary voltage of 1.5 kV in positive ion mode and 2.0 kV in negative ion mode. The source temperature was set to 150 °C, the desolvation temperature to 550 °C, and the desolvation gas flow to 1000 L/h. Routine instrument performance optimization and daily maintenance were conducted weekly to ensure analytical stability. Data acquisition was performed using multiple reaction monitoring (MRM) mode. The cone voltages and collision energies for each transition were optimized using the QuanOptimize application manager (Waters Corp., Milford, MA). The raw UPLC-MS/MS data were initially processed and quantified using TargetLynx version 4.2 (Waters Corp.). Subsequently, peak integration, calibration, quantification, quality control (QC), and batch effect adjustment for each metabolite were performed using TMBQ software (v1.0; Human Metabolomics Institute, Inc., Shenzhen, Guangdong, China), strictly in accordance with the manufacturer’s guidelines. Each metabolite was quantified by calculating the area ratio of the analyte peak to its corresponding stable isotope-labeled internal standard. Calibration curves were generated using at least seven concentration levels, and metabolite concentrations were determined by interpolation from these standard curves. Analytical quality control procedures and the quantitation process were described in the Supporting Methods. Statistical Analysis and Bioinformatics All data modeling and analysis were performed by using iMAP (v1.0; Metabo-Profile, Shanghai, China). Two types of statistical analyses were performed: (1) multivariate statistical analyses including principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA); (2) univariate statistical analyses including Student’s t-test, Mann–Whitney–Wilcoxon (U-test), and fold change (FC). OPLS-DA was used as a supervised method for the predictive modeling purposes. Variable importance in projection (VIP) and univariate statistical analyses were used for potential biomarker selection. Additional methods are provided in the Supporting Information (Figure S1). Results The detailed information on the detected metabolites is shown in Table S1. A total of 180 metabolites were identified and quantified across all study groups (Figure S2a), including amino acids (21.11%), fatty acids (20.56%), organic acids (13.89%), carnitines (11.11%), carbohydrates (9.44%), and others. Figure S2b presents the PCA score plot with corresponding boxplots, and all groups were clearly separated according to PC1 and PC2, indicating the metabolic profiling differences. Compared with the control group, glutamic acid and phenylpyruvic acid were significantly decreased in all types of MMA (Figure S3). Metabolic Analysis of MUT The supervised model OPLS-DA successfully differentiated MUT from controls based on the metabolic profiles (Figure A,B). Through combined multivariate and univariate statistical analyses, 58 potential biomarkers were identified (Table S2, Figure C–F). The nine most significant differential metabolites, ranked by p value, were methylmalonic acid (FC = 150.35), propionylcarnitine (FC = 26.98), methylmalonylcarnitine (FC = 26.12), glutamic acid (FC = 0.52), 3-hydroxyisovaleric acid (FC = 2.34), valerylcarnitine (FC = 4.19), acetylcarnitine (FC = 4.28), phenylpyruvic acid (FC = 0.50), and N-acetylglucosamine (FC = 0.32). The identified differential metabolites are intricately linked to the pathogenesis of MUT-MMA, mitochondrial dysfunction, oxidative stress, and impaired branched-chain amino acid metabolism. On the basis of the 58 potential biomarkers, functional analysis was conducted (Figure G,H). For MUT vs control, glyoxylate and dicarboxylate metabolism, arginine biosynthesis, alanine, aspartate and glutamate metabolism, histidine metabolism, biosynthesis of unsaturated fatty acids, valine, leucine and isoleucine biosynthesis, and pentose phosphate pathway were among the most affected pathways. To refine the biomarker panel, we applied three machine-learning algorithms: random forest (RF), support vector machine (SVM), and Boruta. Intersection analysis produced four shared differential metabolites (Figure I): methylmalonylcarnitine, propionylcarnitine, 2-methylbutyroylcarnitine, and N-acetylglucosamine, with areas under the curve (AUCs) of 1.000 (1, 1), 0.999 (0.997, 1), 0.926 (0.871, 0.980), and 0.895 (0.819, 0.971), respectively (Figure J). Metabolic remodeling analysis between control and MUT. (A) OPLS-DA score plot and (B) permutation plot of Ctrl and MUT. (C) Volcano plot of OPLS-DA model. Volcano plot combines the strength of variable contribution (VIP) and variable reliability (correlation coefficients, Corr. Coeffs, correlation coefficients of each individual metabolite with the first principal component). (D) Volcano plot of univariate statistics. Volcano plot displays FC and p value of each metabolite. (E) Venn diagram of differential metabolites based on OPLS-DA model and univariate statistics. (F) Z score heatmap analysis of potential biomarkers. (G) Enrichment analysis bar plot using pathway-associated metabolite sets. (H) Pathway analysis bubble plot of potential biomarkers. (I) Candidate biomarkers screened based on random forest (RF), support vector machine (SVM) and Boruta analysis. (J) ROC plots of candidate biomarkers with the highest AUCs. AUC, areas under the receiver operating characteristic curve; Ctrl, control; FC, fold change; MUT, methylmalonyl-CoA mutase type methylmalonic acidemia; OPLS-DA, orthogonal partial least squares discriminant analysis; ROC, receiver operating characteristic curve; VIP, variable importance in projection. Among the 42 MUT patients, 30 patients received a standard treatment (MUT_R). Homovanillic acid, oxoglutaric acid, and glycodeoxycholic acid (GDCA) can serve as therapeutic biomarkers (Supporting Information, Figures S4A–I, S5A, Tables S3, and S4). Metabolic Profiles of CblC OPLS-DA modeling effectively distinguished CblC patients from controls (Figure A,B). Multivariate and univariate analyses identified 53 potential biomarkers (Figure C–F, Table S5). Methylmalonic acid (FC = 28.76), methylmalonylcarnitine (FC = 6.57), propionylcarnitine (FC = 9.67), 2-methylbutyroylcarnitine (FC = 2.65), N-α-acetyl-l-lysine (FC = 1.62), linoleic acid (FC = 0.54), glutamic acid (FC = 0.63), 4-hydroxybenzoic acid (FC = 0.39), and phenylpyruvic acid (FC = 0.49) were the most significant differential metabolites. Pathway analysis indicated significant disruptions in amino acid metabolism (alanine, aspartate, glutamate, arginine, histidine, phenylalanine, and glycine/serine/threonine), glyoxylate/dicarboxylate metabolism, and unsaturated fatty acid biosynthesis (Figure G,H). Alterations in lipid metabolites reflect the systemic oxidative stress state and impaired cell membrane phospholipid remodeling induced by the CblC deficiency. This is closely associated with the neurodegenerative damage frequently observed in CblC patients. Further machine-learning analysis identified eight differential metabolites (Figure I). ROC analysis confirmed that the top 4 biomarkers were methylmalonic acid, methylmalonylcarnitine, propionylcarnitine, and 2-methylbutyroylcarnitine, with AUCs ranging from 0.929 to 1.000 (Figure J). Metabolic remodeling analysis between control and CblC. (A) OPLS-DA score plot and (B) permutation plot of Ctrl and CblC. (C) Volcano plot of OPLS-DA model. Volcano plot combines the strength of variable contribution (VIP) and variable reliability (Corr. Coeffs). (D) Volcano plot of univariate statistics. Volcano plot displays FC and p value of each metabolite. (E) Venn diagram of differential metabolites based on OPLS-DA model and univariate statistics. (F) Z score heatmap analysis of potential biomarkers. (G) Enrichment analysis bar plot using pathway-associated metabolite sets. (H) Pathway analysis bubble plot of potential biomarkers. (I) Candidate biomarkers screened based on RF, SVM and Boruta analysis. (J) ROC plots of candidate biomarkers with the highest AUCs. AUC, areas under the receiver operating characteristic curve; Ctrl, control; CblC, cobalamin C type methylmalonic acidemia; FC, fold change; OPLS-DA, orthogonal partial least squares discriminant analysis; ROC, receiver operating characteristic curve; VIP, variable importance in projection. Among the 23 CblC patients, 14 received standard treatment (CblC_R). 4-Hydroxyproline, N-acetylserine, and lactic acid were identified as potential therapeutic biomarkers in CblC after treatment (Supporting Information, Figures S6A–J, S5B, Tables S6, and S7). The metabolic remodeling specific to the CblC_K and CblC_P subtypes is detailed in the Supporting Information (Figures S5C,D, S7–S9, and Tables S8–S12). Metabolic profile variation was observed between CblC and CblC_K (Figure S10A,B), with 47 potential biomarkers identified (Figure S10C–H, Table S13). On the basis of machine learning, the top four biomarkers (AUCs > 0.8) were linoleylcarnitine, isobutyrylcarnitine, oleoylcarnitine, and serine (Figure S10I,J). Furthermore, significant metabolic divergence was observed between the CblC and CblC_P patient groups (Figure S11A–F, Table S14). Pathway analysis indicated marked dysregulation in arginine and proline metabolism as well as glycine, serine, and threonine metabolism (Figure S11G,H). The top four candidate biomarkers for CblC and CblC_P were arginine, 12-hydroxystearic acid, palmitoylcarnitine, and oleoylcarnitine, with AUCs ranging from 0.891 to 0.935 (Figure S11I,J). Clear separation between CblC_K and CblC_P was observed according to their respective metabolic profiles (Figure A–F, Table S15). Pathway enrichment analysis identified glyoxylate and dicarboxylate metabolism as the most significantly perturbed pathways (Figure G,H). Subsequent ROC curve analysis demonstrated that isovalerylcarnitine, phenylacetylglutamine, citraconic acid, and acetic acid effectively differentiated CblC_K from CblC_P. These biomarkers exhibited robust diagnostic performance, with AUCs of 0.958 (0.882, 1), 0.948 (0.855, 1), 0.854 (0.68, 1), and 0.823 (0.595, 1), respectively (Figure I,J). The abnormal fluctuations in key intermediates of the tricarboxylic acid (TCA) cycle and glyoxylate metabolism, such as acetic acid and citraconic acid, may reflect severe mitochondrial energy impairment. The toxic metabolites accumulating in CblC_K patients (isovalerylcarnitine) possess direct cellular toxicity and can act as pro-inflammatory mediators. Metabolic remodeling analysis between CblC_K and CblC_P. (A) OPLS-DA score plot and (B) permutation plot of CblC_K and CblC_P. (C) Volcano plot of OPLS-DA model. Volcano plot combines the strength of variable contribution (VIP) and variable reliability (Corr. Coeffs). (D) Volcano plot of univariate statistics. Volcano plot displays FC and p value of each metabolite. (E) Venn diagram of differential metabolites based on OPLS-DA model and univariate statistics. (F) Z score heatmap analysis of potential biomarkers. (G) Enrichment analysis bar plot using pathway-associated metabolite sets. (H) Pathway analysis bubble plot of potential biomarkers. (I) Candidate biomarkers screened based on RF, SVM, and Boruta analysis. (J) ROC plots of candidate biomarkers with the highest AUCs. AUC, areas under the receiver operating characteristic curve; CblC_K, cobalamin C type methylmalonic acidemia with kidney injury; CblC_P, cobalamin C type methylmalonic acidemia with pulmonary arterial hypertension; FC, fold change; OPLS-DA, orthogonal partial least squares discriminant analysis; ROC, receiver operating characteristic curve; VIP, variable importance in projection. Figure S5E shows that there were two common differential metabolites among CblC vs CblC_K, CblC vs CblC_P, and CblC_K vs CblC_P comparisons. As for the specific differential metabolites, 18 were identified in CblC vs CblC_K, 5 in CblC vs CblC_P, and 10 in CblC_K vs CblC_P (Table ). The similarities and differences in these metabolic profiles reveal the complex pathophysiological network underlying CblC deficiency and its complication-associated subtypes. The overlap and divergence in metabolomic features not only confirm their shared pathogenic origin at the molecular level but also delineate the specific metabolic trajectories associated with distinct organ involvement, providing critical clues for elucidating disease mechanisms and guiding clinical precision medicine. 3Potential Biomarker Analysis of CblC vs. CblC_K, CblC vs. CblC_P, and CblC_K vs. CblC_P CblC vs. CblC_K (unique, n = 18)CblC vs. CblC_P (unique, n = 5)CblC_K vs. CblC_P (unique, n = 10)CblC vs. CblC_K|CblC vs. CblC_P (shared, n = 19)CblC vs. CblC_K|CblC vs. CblC_P|CblC_K vs. CblC_P (shared, n = 2)aminoadipic acid ↓3-methyladipic acid ↑3-hydroxybutyric acid ↑1-methylhistidine ↑|↑12-hydroxystearic acid ↑|↑|↑citrulline ↑dodecanoic acid ↓3-hydroxyisovaleric acid ↑4-hydroxyproline ↑|↑isobutyrylcarnitine ↑|↑|↓dodecanoylcarnitine ↑glucaric acid ↑citraconic acid ↑carnitine ↑|↑ erythronic acid ↓homovanillic acid ↑glycocholic acid ↑creatine ↑|↑glycochenodeoxycholic acidindolelactic acid ↓glycochenodeoxycholic acid 3-sulfate ↑decanoylcarnitine ↑|↑glycoursodeoxycholic acid ↓ N-acetylserine ↑galactonic acid ↓|↓isocaproic acid ↓pipecolic acid ↑glycohyocholic acid ↓|↓linoleic acid ↑ribonic acid ↓glycylproline ↓|↓lysine ↓sebacic acid ↑hexanoylcarnitine ↑|↑methylmalonic acid ↓tridecanoic acid ↑hydroxypropionic acid ↓|↓myristoleic acid ↑ linoleylcarnitine ↑|↑ N-acetyltryptophan ↓octanoylcarnitine ↑|↑ N-acetyltyrosine ↓oleoylcarnitine ↑|↑octanoic acid ↓palmitoylcarnitine ↑|↑pyrrole-2-carboxylic acidphenylalanyltryptophan ↓|↓quinolinic acid ↓sarcosine ↑|↑stearoylcarnitine ↑taurocholic acid ↓|↓threonine ↓taurochenodeoxycholic acid ↓|↓ tetradecanoylcarnitine ↑|↑aAbbreviations: CblC, cobalamin C type methylmalonic acidemia; CblC_K, cobalamin C type methylmalonic acidemia with kidney injury; CblC_P, cobalamin C type methylmalonic acidemia with pulmonary arterial hypertension; vs., versus. Arrows indicate significantly increased (↑) or decreased (↓) levels in the right group compared with the left group. Potential Biomarker Analysis of CblC vs. CblC_K, CblC vs. CblC_P, and CblC_K vs. CblC_P Abbreviations: CblC, cobalamin C type methylmalonic acidemia; CblC_K, cobalamin C type methylmalonic acidemia with kidney injury; CblC_P, cobalamin C type methylmalonic acidemia with pulmonary arterial hypertension; vs., versus. Arrows indicate significantly increased (↑) or decreased (↓) levels in the right group compared with the left group. Comparative Metabolic Analysis between MUT and CblC The purpose of this analysis was to elucidate metabolic distinctions between MUT and CblC. The OPLS-DA model successfully differentiated samples according to their individual metabolic profiles (Figure A,B). A total of 36 potential biomarkers were identified (Figure C–F, Table S16). The top nine differential metabolites (ordered by p value) were acetylcarnitine, methylmalonylcarnitine, propionylcarnitine, 3-hydroxylisovalerylcarnitine, glycine, stearoylcarnitine, butyrylcarnitine, hexanoylcarnitine, and valerylcarnitine. For MUT vs CblC, glycine, serine, and threonine metabolism and glutathione metabolism were among the most affected pathways (Figure G,H). Further screening of the 36 potential biomarkers using RF, SVM, and Boruta yielded two common differential metabolites: methylmalonylcarnitine and linoleylcarnitine (Figure I), with AUCs of 0.940 (0.875, 1) and 0.818 (0.712, 0.924), respectively (Figure J). Although both subtypes lead to elevated methylmalonylcarnitine, the significant differences observed may reflect variations in residual enzyme activity, compensatory capacity via alternative metabolic pathways, or the severity of mitochondrial dysfunction between a primary enzyme protein defect (MUT) and a cofactor synthesis defect (CblC). Metabolic remodeling analysis between MUT and CblC. (A) OPLS-DA score plot and (B) permutation plot of MUT and CblC. (C) Volcano plot of OPLS-DA model. Volcano plot combines the strength of variable contribution (VIP) and variable reliability (Corr. Coeffs). (D) Volcano plot of univariate statistics. Volcano plot displays FC and p value of each metabolite. (E) Venn plot of differential metabolites based on OPLS-DA model and univariate statistics. (F) Z score heatmap analysis of potential biomarkers. (G) Enrichment analysis bar plot using pathway-associated metabolite sets. (H) Pathway analysis bubble plot of potential biomarkers. (I) Candidate biomarkers screened based on RF, SVM and Boruta analysis. (J) ROC plots of candidate biomarkers with the highest AUCs. AUC, area under the receiver operating characteristic curve; CblC, cobalamin C type methylmalonic acidemia; FC, fold change; MUT, methylmalonyl-CoA mutase type methylmalonic acidemia; OPLS-DA, orthogonal partial least squares discriminant analysis; ROC, receiver operating characteristic curve; VIP, variable importance in projection. Figure S5F shows that there were 12 shared differential metabolites among the control vs MUT, control vs CblC, and MUT vs CblC comparisons. As for the unique differential metabolites, 15 were identified in control vs MUT, 10 in control vs CblC, and 8 in MUT vs CblC (Table ). The identified differential metabolites not only validate the shared blockade in the methylmalonic acid metabolic pathway between MUT and CblC-type MMA but also, through alterations in glutathione, amino acid, and lipid metabolism pathways, reveal subtype-specific differences in oxidative stress levels, neurotoxicity mechanisms, and the extent of mitochondrial dysfunction. 4Potential Biomarker Analysis of Ctrl vs. MUT, Ctrl vs. CblC and MUT vs. CblC Ctrl vs. MUT (unique, n = 15)Ctrl vs. CblC (unique, n = 10)MUT vs. CblC (unique, n = 8)Ctrl vs. MUT|Ctrl vs. CblC (shared, n = 23)Ctrl vs. MUT|Ctrl vs. CblC|MUT vs. CblC (shared, n = 12)2-butenoic acid ↑α-linolenic acid ↓creatine ↓2-furoic acid ↑|↑3-hydroxyisovaleric acid ↑|↑|↓2-hydroxycaproic acid ↓butyric acid ↑glycochenodeoxycholic acid ↓2-methylbutyroylcarnitine ↑|↑3-hydroxylisovalerylcarnitine ↑|↓|↓2-methy-4-pentenoic acid ↓ethylmethylacetic acid ↑homovanillic acid ↓4-hydroxybenzoic acid ↓|↓decanoylcarnitine ↑|↓|↓adipic acid ↑glucaric acid ↓isovalerylcarnitine ↓acetic acid ↑|↑glutamic acid ↓|↓|↑adenosine monophosphate ↓isocaproic acid ↑lactose ↑aminoadipic acid ↑|↑glycine ↑|↓|↓fructose ↓maleic acid ↑ ortho-hydroxyphenylacetic acid ↓arachidonic acid ↓|↓hydroxypropionic acid ↑|↑|↓gluconic acid ↓ N-acetylglutamine ↑phenylacetylglutamine ↓arginine ↓|↓linoleylcarnitine ↑|↓|↓gluconolactone ↓phenylalanine ↓sarcosine ↑aspartic acid ↓|↓methylmalonic acid ↑|↑|↓glyceraldehyde ↓picolinic acid ↓ caproic acid ↑|↑methylmalonylcarnitine ↑|↑|↓lactic acid ↑pyruvic acid ↓citric acid ↓|↓octanoylcarnitine ↑|↓|↓mannose ↓ eicosapentaenoic acid ↓|↓propionylcarnitine ↑|↑|↓ O-adipoylcarnitine ↑glyceric acid ↓|↓valerylcarnitine ↑|↑|↓pimelic acid ↓imidazoleacetic acid ↓|↓ pyrrole-2-carboxylic acid ↓indole-3-carboxaldehyde ↓|↓threonine ↓indole-3-carboxylic acid ↓|↓ linoleic acid ↓|↓ N-acetylaspartic acid ↓|↓ N-acetylglucosamine ↓|↓ N-α-acetyl-l-lysine ↑|↑oleic acid ↓|↓phenylpyruvic acid ↓|↓ribulose and xylulose ↓|↓valeric acid ↑|↑aAbbreviations: Ctrl, control; CblC, cobalamin C type methylmalonic acidemia; MUT, methylmalonyl-CoA mutase type methylmalonic acidemia. vs., versus. Arrows indicate significantly increased (↑) or decreased (↓) levels in the right group compared with the left group. Potential Biomarker Analysis of Ctrl vs. MUT, Ctrl vs. CblC and MUT vs. CblC Abbreviations: Ctrl, control; CblC, cobalamin C type methylmalonic acidemia; MUT, methylmalonyl-CoA mutase type methylmalonic acidemia. vs., versus. Arrows indicate significantly increased (↑) or decreased (↓) levels in the right group compared with the left group. Discussion MMA prevalence is increasing globally, and various MMA subtypes exist, underlining the need for pathophysiological studies and novel intervention strategies. , However, the absence of early symptoms, the limitations in current diagnostic methods, and the insufficient research on the pathogenesis all pose challenges in this regard. , Therefore, identifying specific biomarkers for MMA subtypes that enable precise diagnosis, elucidation of etiopathogenesis, and targeted intervention holds significant clinical and research value. Metabolomics is indeed a powerful tool for studying the abnormal metabolites within organisms, ,− and its application in research on the main MMA subtypes (MUT, CblC, CblC_K, and CblC_P) can provide valuable insights into the underlying pathological mechanisms of this disorder. Different Metabolic Patterns in MUT and CblC While both MUT and CblC deficiencies result in methylmalonic acidemia due to impaired methylmalonyl-CoA mutase activity, their metabolic signatures diverge significantly, reflecting the distinct roles of the defective proteins within the cobalamin pathway. The MUT subtype, caused by mutations in the MMUT gene, represents an isolated defect in the mitochondrial conversion of methylmalonyl-CoA to succinyl-CoA. In contrast, the CblC subtype arises from mutations in MMACHC, which impair the intracellular synthesis of the active cobalamin cofactorsadenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). These cofactors are essential for the function of methylmalonyl-CoA mutase (MUT) and methionine synthase (MTR), respectively. , The resulting dual enzymatic block causes the systemic accumulation of methylmalonic acid, methylcitrate, and homocysteine, along with methionine depletion, ultimately culminating in severe multisystem damage. On the basis of targeted metabolomics, credible models with clear separations were achieved between MUT, CblC, and control underpinned by the metabolic pattern similarity in each group. These metabolites, including creatine, glycochenodeoxycholic acid, homovanillic acid, isovalerylcarnitine, lactose, ortho-hydroxyphenylacetic acid, phenylacetylglutamine, and sarcosine, demonstrated potential as diagnostic biomarkers for differentiating CblC and MUT subtypes (Table ). Collectively, the identification of these eight metabolites reveals distinct metabolic trajectories underlying the MMA pathogenesis. In the MUT subtype, marked elevations in isovalerylcarnitine, phenylacetylglutamine, and glycochenodeoxycholic acid reflect a triad of severe mitochondrial toxicity, extreme hepatic detoxification burden, and acute metabolic decompensation. ,,,, In contrast, the CblC subtype is characterized by a profound depletion of the methyl pool. , The significantly lower level of creatine and higher level of sarcosine directly signify the failure of methionine synthase, while the reduced concentrations of neurotransmitter metabolites (homovanillic acid and orthohydroxyphenylacetic acid) point to critical deficits in neurotransmitter biosynthesis. ,− Furthermore, the elevated lactose in CblC patients suggests chronic gastrointestinal dysfunction driven by persistent metabolic derangement. These findings underscore that MUT-MMA manifests primarily as an acute visceral crisis, whereas CblC-MMA evolves as a chronic disorder of methyl and neurotransmitter exhaustion. This would be a great addition to the present biomarkers for differentiating MUT from those of CblC-MMA. However, to our knowledge, previous studies have not focused on these potential biomarkers between MUT and CblC-MMA, which merit further exploration of these biomarkers and the detailed physiological and pathological roles in the MMA condition. Additionally, validation experiments are necessary for the precision and specificity of these biomarkers, which could be validated in a larger MMA cohort by using MS-based targeted metabolomics. A few recent studies have reported metabolic profiling in plasma, urine, and DBS from MUT and/or CblC-MMA patients. − ,,, Our results are in accordance with these studies, which showed notable metabolic disturbances of amino acids and organic acids, indicating profound metabolic pathway remodeling. Our study also pointed out that various carnitines, fatty acids, carbohydrates, and ketones were significantly altered in the MMA patients. In MUT-MMA patients, 3-hydroxylisovalerylcarnitine and linoleylcarnitine were markedly increased; after treatment, these two metabolites were further elevated. The underlying explanation could be that following treatment with free carnitine supplementation, the levels of acylcarnitines, including 3-hydroxylisovalerylcarnitine and linoleylcarnitine, increased. Mannose was significantly decreased in MUT-MMA patients, and after treatment, the metabolite was further reduced (Table S4). Mannose is essential for protein glycosylation and participates in the synthesis of most glycoproteins and secretory proteins in the body as well as in regulating metabolic processes. It also exhibits functions including inhibiting bacterial adhesion, exerting anti-inflammatory and antitumor effects, and regulating glycolipid metabolism. In the present study, mannose remained at a lower level in MUT following treatment, and the underlying reason warrants further investigation. N-Acetylaspartic acid and pyruvic acid were decreased in CblC and were further reduced after treatment (Table S7). N-Acetylaspartic acid can be synthesized in neurons from aspartate and acetyl-CoA. The primary proposed functions include acting as a neuronal osmolyte that is involved in fluid balance in the brain, serving as a precursor for the synthesis of the important dipeptide neurotransmitter N-acetylaspartylglutamate, serving as a source of acetate for lipid and myelin synthesis in oligodendrocytes, and playing a potential role in energy production in neuronal mitochondria. However, high N-acetylaspartic acid levels can lead to abnormal neural signaling, delayed or arrested intellectual development, and difficulty in general motor skills. N-Acetylaspartic acid can be a neurotoxin and a metabotoxin at sufficiently high levels. Pyruvic acid can be made from glucose through glycolysis and converted back to carbohydrates (such as glucose) via gluconeogenesis or to fatty acids through a reaction with acetyl-CoA. Pyruvic acid metabolism warrants further investigation. Different Metabolic Patterns in CblC, CblC_K, and CblC_P While the primary biochemical hallmarks of CblC deficiencyspecifically the accumulation of methylmalonic acid and homocysteineare well established, , the downstream metabolic reprogramming that drives distinct clinical phenotypes remains incompletely understood. The precise mechanisms linking the intracellular cobalamin defect to specific systemic complications, such as PAH and kidney injury, remain elusive and likely involve broader metabolic network perturbations extending beyond the canonical pathways. To address this, we employed targeted metabolomics to comprehensively characterize the metabolic profiles of CblC-MMA complicated by kidney injury and PAH. By comparing these distinct metabolic signatures, we aim to identify novel biomarkers and elucidate the specific pathophysiological pathways contributing to the multisystem damage observed in CblC-MMA. To depict the interrelationships among the metabolic impairment data from the CblC vs CblC_K, CblC vs CblC_P, and CblC_K vs CblC_P comparisons, a Venn diagram was constructed (Figure S5E, Table ). To our knowledge, this is the first study to identify distinct metabolomic signatures differentiating kidney injury from PAH in CblC patients. Notably, CblC_P was characterized by a broad metabolic storm involving nine unique biomarkers, reflecting concurrent mitochondrial energy failure (3-hydroxybutyric acid, citraconic acid, sebacic acid), bile acid-mediated endothelial toxicity (glycocholic acid and glycochenodeoxycholic acid 3-sulfate), branched-chain amino acid catabolic impairment (3-hydroxyisovaleric acid), neuro-immune metabolic dysregulation (N-acetylserine and pipecolic acid), and aberrant lipid signaling (tridecanoic acid). ,,, In contrast, CblC_K exhibited a singular elevation of ribonic acid, suggesting a more localized compensatory activation of the pentose phosphate pathway in response to oxidative-stress-driven tubular injury. , This metabolomics-driven perspective provides molecular evidence for understanding disease heterogeneity and points the way toward early subtype diagnosis and individualized precision treatment. , Metabolic remodeling involving medium- and long-chain fatty acids (LCFAs) and long-chain acylcarnitines was first reported in CblC patients. Medium-chain fatty acids (MCFAs) could modulate tissue metabolism of carbohydrates and lipids, as manifested by a mostly inhibitory effect on glycolysis and stimulation of lipogenesis or gluconeogenesis. Long-chain fatty acids (LCFAs) with 14–20 carbons mainly regulate energy metabolism in organisms, and more than 15 enzymes are involved in long-chain fatty acid oxidation. Pathogenic mutations in genes encoding enzymes involved in long-chain fatty acid oxidation result in the accumulation of long-chain acylcarnitines, leading to compromised energy homeostasis. Several significantly changed bile acids were also observed in CblC patients. Bile acids act as strong signaling molecules through different nuclear receptors and cell signaling pathways to regulate lipid, glucose, and energy metabolism. These results indicate that further studies of CblC should focus on medium- and long-chain fatty acids. The application of quantitative metabolomics was also evaluated for CblC_K before and after treatment, though only 5 patients received standard therapy. Pyrrole-2-carboxylic acid was markedly decreased in CblC_K; however, after treatment, this metabolite was significantly increased. Pyrrole-2-carboxylic acid could be used as a biomarker for therapeutic response in CblC_K. It was first identified as a degradation product of sialic acids and later as a derivative of the oxidation of the d-hydroxyproline isomers. Due to the limited sample size, this finding needs to be evaluated in forthcoming research. Because only two CblC_P patients received standard therapy, metabolic remodeling related to treatment was not evaluated in the present study. The major limitation of this research is the relatively small sample size for statistical analysis, especially for patients who received a standard therapy. Small cohort studies may increase selection bias and limit the generalizability of the findings. The rarity of MMA and hence the limited availability of cohorts impose an inherent limitation on this study. Future research involving multicenter studies and independent MMA cohorts is necessary to improve the statistical power and thereby validate potential biomarkers identified in this research. Consequently, the metabolites identified in this study should be interpreted as strong candidate drivers or biomarkers associated with MUT-MMA or CblC-MMA rather than definitively proven causal factors. To overcome this limitation, our laboratory is currently developing relevant MMA animal models to functionally validate the pathogenic roles of these key altered metabolites. Furthermore, we are actively engaged in the prospective collection of fresh plasma samples, which will facilitate future targeted validation studies and help to distinguish primary disease-driving mechanisms from secondary metabolic alterations. Additionally, the specified metabolites showing promising discriminatory efficacy were identified on the basis of DBS samples. Further investigations using other biological samples (plasma, urine, or cerebrospinal fluid) from MMA patients would provide a much more comprehensive understanding of the metabolic remodeling. This study provides comprehensive DBS-based quantitative metabolic profiling (MUT, CblC, CblC_K, and CblC_P). Different metabolome panels revealed metabolic remodeling and various etiopathogenesis mechanisms in MMA patients. MUT and CblC patients exhibit different metabolite clusters; unique metabolites were identified that could be utilized to reveal the underlying specific pathogenesis. Regarding CblC, CblC_K, and CblC_P, unique potential biomarkers were screened to differentiate these three subtypes. Apart from common amino acids and organic acids, several other metabolites (bile acids, fatty acids, carbohydrates, pyridines, and indoles), which have not been studied in previous CblC patients, deserve to be clarified in depth in future precise metabolomics associated with CblC. Furthermore, we identified pyrrole-2-carboxylic acid as a biomarker for therapeutic response in CblC_K patients. Metabolome profiling is a promising tool for elucidating disease mechanisms and monitoring inherited organic-acid metabolic disorders. Pathophysiological interpretation based on metabolomics may open new therapeutic strategies for the treatment of MMA. Supplementary Material